TOLVAPTAN: payments to doctors
Payments that named TOLVAPTAN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.9M
- Providers
- 53
- Transactions
- 507
- Average per transaction
- $3,761
The per-transaction average — $3,761 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 53 providers the average total is $35,975, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,884,763 | 98.9% |
| Otsuka America Pharmaceutical, Inc. | $21,908 | 1.1% |